Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) and C4 Therapeutics (NASDAQ:CCCC – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.
Volatility & Risk
Tenaya Therapeutics has a beta of 2.87, indicating that its stock price is 187% more volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 3.07, indicating that its stock price is 207% more volatile than the S&P 500.
Valuation & Earnings
This table compares Tenaya Therapeutics and C4 Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tenaya Therapeutics | $1.33 million | 62.82 | -$90.60 million | ($0.53) | -0.71 |
| C4 Therapeutics | $35.95 million | 9.84 | -$104.99 million | ($1.00) | -2.88 |
Tenaya Therapeutics has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Tenaya Therapeutics and C4 Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tenaya Therapeutics | N/A | -83.75% | -66.53% |
| C4 Therapeutics | -289.44% | -45.45% | -30.90% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Tenaya Therapeutics and C4 Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tenaya Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
| C4 Therapeutics | 1 | 0 | 3 | 0 | 2.50 |
Tenaya Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 969.52%. C4 Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 195.65%. Given Tenaya Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Tenaya Therapeutics is more favorable than C4 Therapeutics.
Institutional & Insider Ownership
90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Tenaya Therapeutics beats C4 Therapeutics on 10 of the 15 factors compared between the two stocks.
About Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
